Prognostic value of plasmatic tumor M2 pyruvate kinase and carcinoembryonic antigen in the survival of colorectal cancer patients

Fatela-Cantillo, Daniel; Fernández-Suárez, Antonio; Moreno, Miguel Alonso Marín; Gutiérrez, J.J. Puente; Iglesias, José Miguel Díaz

doi:10.1007/s13277-011-0304-0

Cited by 8 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fluorescent bioprobes are useful tools for optical imaging and analytical sensing, which allow direct visualization of biological macromolecules at the molecular level, facilitating the diagnosis of diseases. Recently, several lines of evidence confirmed that PKM2 had high sensitivity in the auxiliary diagnosis of various types of cancers, indicating that PKM2 has a potential application value in the early detection of cancer, prognostic judgment, and anti-tumor effect evaluation . In this study, for the first time, we designed and synthesized a novel PKM2 bioprobe by conjugating a PKM2 activator TEPP-46 with the fluorophore coumarine.…”

Section: Discussionmentioning

confidence: 90%

“…Recently, several lines of evidence confirmed that PKM2 had high sensitivity in the auxiliary diagnosis of various types of cancers, indicating that PKM2 has a potential application value in the early detection of cancer, prognostic judgment, and anti-tumor effect evaluation. 38 In this study, for the first time, we designed and synthesized a novel PKM2 bioprobe by conjugating a PKM2 activator TEPP-46 with the fluorophore coumarine. This bioprobe TEPC466 was designed to induce the formation of the PKM2 tetramer and emit fluorescence via the AIE effect.…”

Section: ■ Conclusionmentioning

confidence: 99%

See 1 more Smart Citation

TEPP-46-Based AIE Fluorescent Probe for Detection and Bioimaging of PKM2 in Living Cells

Wang

Zhu

et al. 2021

Anal. Chem.

View full text Add to dashboard Cite

Pyruvate kinase (PK) M2 (PKM2), a glycolytic enzyme, is a hallmark of different types of tumors and plays a significant role in the Warburg effect. However, there is no fluorescent probe for PKM2 that has been reported yet. In this study, TEPC466, a novel TEPP-46-based aggregation-induced emission (AIE) probe for the detection of PKM2, was designed, synthesized, and fully characterized by 1H NMR, 13C NMR, and high-resolution mass spectrometry. When the fluorescent agent, coumarine, was conjugated to TEPP-46, the bioprobe TEPC466 showed a high degree of selectivity and sensitivity for the detection of PKM2 protein via the AIE effect. TEPC466 was then successfully applied in imaging the PKM2 protein in colorectal cancer cells with low toxicity. Moreover, structure-based modeling and the PK activity assay confirmed that TEPC466 has a better binding with PKM2 than TEPP-46, which suggests that TEPC466 could also be a good agonist of PKM2. Taken together, the bioprobe shows potential in selective detection of PKM2 and provides a useful tool for cancer diagnosis and therapy.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: ■ Conclusionmentioning

confidence: 99%

TEPP-46-Based AIE Fluorescent Probe for Detection and Bioimaging of PKM2 in Living Cells

Wang

Zhu

et al. 2021

Anal. Chem.

View full text Add to dashboard Cite

show abstract

“…A total of 732 patients showed a CEA-pre of <5 ng/mL, and these patients would be classified into the “normal group” according to the criteria used in previous studies ( 5 , 7 , 8 , 10 – 12 ). Among them, 362, 280, and 90 patients were classified into the normal, normalized, and elevated groups based on the CEA-trend classification in the present study.…”

Section: Resultsmentioning

confidence: 99%

Clinical Significance of Early Carcinoembryonic Antigen Change in Patients With Nonmetastatic Colorectal Cancer

Lee

Cho

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThis study aimed to evaluate the prognostic significance of preoperative, postoperative, and trajectory changes in carcinoembryonic antigen (CEA) levels in patients with colorectal cancer (CRC).MethodsThis retrospective study included patients who underwent surgical resection for nonmetastatic CRC. The optimal cutoff values of preoperative CEA (CEA-pre), early postoperative CEA (CEA-post), and CEA level change (CEA-delta) were determined to maximize the differences in overall survival (OS) among groups. The patients were divided into three groups according to CEA-trend: normal, low CEA-pre; normalized, high CEA-pre/low CEA-post; elevated, high CEA-pre/high CEA-post. The integrated area under the curve (iAUC) was used to compare the discriminatory power of all variables.ResultsA total of 1019 patients diagnosed with stage I–III CRC were enrolled. The optimal cutoff values of CEA level were determined as 2.3 ng/mL for CEA-pre, 2.3 ng/mL for CEA-post, and -0.93 ng/mL for CEA-delta. Although subgroup dichotomization showed that CEA-pre, CEA-post, CEA-delta, and CEA-trend were all associated with OS in univariate analysis, CEA-trend was the only independent prognostic factor in multivariate analysis. The iAUC of CEA-trend was superior to that of CEA-pre, CEA-post, and CEA-delta. Compared with the normal group, the normalized group showed worse OS (p=.0007) in stage II patients but similar OS (p=.067) in stage III patients.ConclusionThe optimal cutoff value of CEA level in the preoperative and postoperative periods was determined to be 2.3 ng/mL, and the combination of CEA-pre and CEA-post showed better prognostic stratification. However, its prognostic significance may differ depending on the CRC stage.

show abstract

“…Tumour pyruvate kinase M2 (M2-PK) is a key enzyme in the altered metabolism of tumour tissues. It is present in high concentrations in malignant tissues, plasma, and other body fluids 40,41 . Together with other tumour markers plasmatic and faecal levels of M2-PK could be used for prognosis.…”

Section: Colorectal Cancermentioning

confidence: 99%

Laboratory screening markers in gastroenterology - state of the art

Kocna¹,

Vaníčková²,

Zima³

2013

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Introduction. Screening tests for gastrointestinal diseases acceptable for population with a high sensitivity and high specificity can now be offered by clinical laboratories. This paper summarizes major recent advances in this area of laboratory medicine. Methods. Relevant articles published within the last 5 years in the NLM (National Library of Medicine) PubMed -Medline database covering the three gastrointestinal diseases -colorectal cancer, coeliac disease, and atrophic gastritis were included for this overview. Results. In Europe, colorectal cancer (CRCA) is the second most frequent malignant disease. Quantitative immunochemical analysis of the stool for haemoglobin provides the best screening test to date, with both sensitivity and specificity approaching 95%. Even though coeliac disease (CD) affects approximately 1% of the general population, it remains largely unrecognised. Recommended methods for screening currently involve the detection of IgA and IgG antibodies against tissue transglutaminase and deamidated gliadin peptide. Evaluations of screening are now discussed for other diseases of the gastrointestinal tract -such as chronic atrophic gastritis (CAG), and inflammatory bowel disease (IBD). Detection of infection by Helicobacter pylori and stomach-specific plasmatic biomarkers, especially pepsinogen I/II ratio, could help with the prevention of gastric carcinomas. The use of faecal calprotectin as a screening test could substantially reduce the number of invasive methods necessary for the diagnostic work-up of patients with IBD. Conclusions. Screening tests for CRCA and CD have been used worldwide for many years. Screening strategies for gastrointestinal diseases are suggested in the text, based on recent basic science, clinical papers as well as our own experience.

show abstract

Prognostic value of plasmatic tumor M2 pyruvate kinase and carcinoembryonic antigen in the survival of colorectal cancer patients

Cited by 8 publications

References 21 publications

TEPP-46-Based AIE Fluorescent Probe for Detection and Bioimaging of PKM2 in Living Cells

TEPP-46-Based AIE Fluorescent Probe for Detection and Bioimaging of PKM2 in Living Cells

Clinical Significance of Early Carcinoembryonic Antigen Change in Patients With Nonmetastatic Colorectal Cancer

Laboratory screening markers in gastroenterology - state of the art

Contact Info

Product

Resources

About